All In Biotech

Drug Trial Radar · NCT04650542

Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects

Open-Label, Two-Period Phase 1 Study in Healthy Subjects to Evaluate the Potential Effect of Multiple Doses of Paroxetine on the Pharmacokinetics and Safety of HBI-3000

Last checked: Nov 20, 2026Latest source record: Jul 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

39

Actual

Start

Feb 21, 2021

Primary completion

Aug 13, 2021

Study completion Aug 13, 2021

Sponsor

Lead sponsor
HUYABIO International, LLC.Industry
Sponsor type
Industry
First posted
Dec 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects

Conditions

  • Drug-drug Interaction

Interventions

  • HBI-3000Drug

    small molecule, multi-ion channel blocker

  • ParoxetineDrug

    serotonin uptake inhibitor, CYP2D6 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma pharmacokinetics (PK): Maximum observed plasma concentration (Cmax)Time frame: 72 hours
  2. Plasma pharmacokinetics (PK): Area Under the Curve (AUC) from time 0 to last measurable concentration (AUC0 - tau)Time frame: 72 hours
  3. Plasma pharmacokinetics (PK): Area Under the Curve (AUC) from time 0 to infinity (AUC0 - infinity), if data permitsTime frame: 72 hours

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Spaulding Clinical

    West Bend, Wisconsin

  • Nucleus Network Pty Ltd.

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.